![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Understanding “Delinking” in the PBM Legislation | AMCP 2024
2024年4月16日 · Many of the new rules Congress is considering in the still-fluid pharmacy benefit management (PBM) legislation would add reporting requirements to meet transparency goals but wouldn’t fundamentally disrupt the industry’s business practices.
Optum Rx Switches Up Humira Biosimilar Coverage for 2025
2024年12月9日 · Beginning Jan. 1, 2025, Optum Rx will prefer a different set of Humira biosimilar on its commercial formularies. UnitedHealth Group’s pharmacy benefit manager (PBM), one of the three largest in the United States, is favoring Amgen’s Amjevita (adalimumab-atto) over Sandoz’s Hyrimoz (adalimumab-adaz) and Cyltezo (adalimumab-adbm).
CVS Caremark Makes Changes in Diabetes Coverage for 2025
2024年11月25日 · CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
SMA Drugs Jockey for Position in the Marketplace
2024年11月16日 · The recent round of third-quarter earnings reports by spinal muscular atrophy (SMA) drugmakers provided a snapshot on how these medicines are performing around the world for the year to date and offered insights into how the companies are looking to expand their offerings to untreated patients next year.
Pressure on Patient Assistance Programs | Predictions for 2025
2025年1月9日 · Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access. With a new administration in place, many are focused on federal healthcare changes. But in 2025, the bigger challenges will come from how payers and states handle costs ...
UnitedHealthcare Adds Deductibles to Medicare Part D for 2025
2024年10月3日 · UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.
Nonsteroidal Drug for Duchenne Launches with a $700,000 Price Tag
2024年7月25日 · Duvyzat was approved in March 2024 and works to reduce the inflammation and loss of muscle experienced by patients with Duchenne muscular dystrophy.
Express Scripts and Cigna Add Zepbound to Formularies
Effective Dec. 1, 2023, Lilly’s Zepbound (tirzepatide) was added to the national preferred formulary for Express Scripts and Cigna Healthcare.
What’s Changed In Hospice in 2024? - Managed Healthcare …
2024年8月5日 · Physician eligibility. Another change in the 2024 fiscal year is that CMS now requires that doctors who certify patients to be eligible for hospice care to be enrolled as a Medicare provider or be opted out in a valid manner.
A Hot Take: What the Trump Win Will Mean for U.S. Healthcare
2024年11月6日 · Johnson, a Louisiana Republican, referenced the GOP Doctors Caucus as a source of healthcare ideas. In the current Congress, the caucus consists of 16 Republicans physicians, pharmacists and dentists and is chaired by Rep. Andrew Harris, Maryland’s only Republican congressman and an obstetric anesthesiologist.